ACW (ASX) Ann: Review of 2020 and outlook

Originally posted by US10: ↑

We in the States are pleased to report the recent removal of our demon president. We can now focus on a small gem of a medical company in Australia.

My views have become higher level and simplified. I remain a major shareholder in the company - watching the stock price with pain and impatiently accepting delays in proof of efficacy despite the urgency of illness. This is the story of cortisol. We have a drug that works to reduce the production of certain forms and sources of cortisol and it has been certified as relatively safe. We now have to find a market(s) composed of target populations that would most benefit from the reduction of the specific cortisol element. The task is to research and prove just what problems cortisol reduction can effectively address. We do know that such raised cortisol elements have been found in a variety of cognitive, psychological, communicable and physiological debilitations. I believe the odds of finding significant direct or indirect cortisol caused debilitations is very high. Here is what I expect to happen:

1) There will continue to be evidence of cognitive benefit for AD patients as shown with the new trial. 2+ years out. The approval process and path to a final product will be speeded up and other companies will come on board.
2) Fragile X is one of many possible debilitations that could benefit from Xanamem. It makes marketing, development and scientific sense to choose this out of the gate.
3) The company will continue to look for research partners, grant partners and co-development partners for Xanamem for a variety of debilitations - as preventatives or correctives - with or without a second drug pairing. I am quite optimistic that there will be valuable new developments in 2021. I expect Actinogen to induce many existing research studies to include cortisol measurement as a part of their study protocol - contributing to the eventual proof of the cortisol hypothesis for a variety of debilitations.

We own a safe drug that effectively reduces specific forms of cortisol. I believe big pharma will ultimately jump in not only for specific applications but for a massive general cognitive/physiological/aging health market like cholesterol control drugs (statins) did for heart disease. While I remain all in, I recognize the inherent risk of a small company developing a unique new drug for major markets. Best Wishes to ALL.

Expand

If actinogen could pump your new puppet president full of xanamem .that would be a good thing for the american people and the share price .If any one needs this product its Joe .Whats he on now.?

Originally posted by US10: ↑

We in the States are pleased to report the recent removal of our demon president. We can now focus on a small gem of a medical company in Australia.

My views have become higher level and simplified. I remain a major shareholder in the company - watching the stock price with pain and impatiently accepting delays in proof of efficacy despite the urgency of illness. This is the story of cortisol. We have a drug that works to reduce the production of certain forms and sources of cortisol and it has been certified as relatively safe. We now have to find a market(s) composed of target populations that would most benefit from the reduction of the specific cortisol element. The task is to research and prove just what problems cortisol reduction can effectively address. We do know that such raised cortisol elements have been found in a variety of cognitive, psychological, communicable and physiological debilitations. I believe the odds of finding significant direct or indirect cortisol caused debilitations is very high. Here is what I expect to happen:

1) There will continue to be evidence of cognitive benefit for AD patients as shown with the new trial. 2+ years out. The approval process and path to a final product will be speeded up and other companies will come on board.
2) Fragile X is one of many possible debilitations that could benefit from Xanamem. It makes marketing, development and scientific sense to choose this out of the gate.
3) The company will continue to look for research partners, grant partners and co-development partners for Xanamem for a variety of debilitations - as preventatives or correctives - with or without a second drug pairing. I am quite optimistic that there will be valuable new developments in 2021. I expect Actinogen to induce many existing research studies to include cortisol measurement as a part of their study protocol - contributing to the eventual proof of the cortisol hypothesis for a variety of debilitations.

We own a safe drug that effectively reduces specific forms of cortisol. I believe big pharma will ultimately jump in not only for specific applications but for a massive general cognitive/physiological/aging health market like cholesterol control drugs (statins) did for heart disease. While I remain all in, I recognize the inherent risk of a small company developing a unique new drug for major markets. Best Wishes to ALL.

Expand

No.	Vol.	Price($)
3	126537	3.5¢

No.

Vol.

Price($)

126537

3.5¢

Price($)	Vol.	No.
3.3¢	95163	2

Price($)

Vol.

No.

3.3¢

95163

No.	Vol.	Price($)
3	126537	0.035
1	352371	0.034
3	645000	0.033
3	482313	0.032
2	612580	0.031

No.

Vol.

Price($)

126537

0.035

352371

0.034

645000

0.033

482313

0.032

612580

0.031

Price($)	Vol.	No.
0.033	95163	2
0.034	2615	1
0.035	41250	2
0.036	370803	2
0.037	94724	2

Price($)

Vol.

No.

0.033

95163

0.034

2615

0.035

41250

0.036

370803

0.037

94724

(20min delay)
Last 3.5¢		Change 0.000(0.00%)		Mkt cap ! $94.93M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Winsome scoping study proposes low-cost operation for Adina lithium project

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Winsome scoping study proposes low-cost operation for Adina lithium project

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News